{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:25:50Z","timestamp":1790623550405,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["Theradnet No # 860245 (to MV)"],"award-info":[{"award-number":["Theradnet No # 860245 (to MV)"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["ERC CoG 617060 to MV"],"award-info":[{"award-number":["ERC CoG 617060 to MV"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001722","name":"Koninklijke Nederlandse Akademie van Wetenschappen","doi-asserted-by":"publisher","award":["early career award 2021"],"award-info":[{"award-number":["early career award 2021"]}],"id":[{"id":"10.13039\/501100001722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012623","name":"Federation of European Biochemical Societies","doi-asserted-by":"publisher","award":["FEBS excellence award 2021"],"award-info":[{"award-number":["FEBS excellence award 2021"]}],"id":[{"id":"10.13039\/100012623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"DOI":"10.1186\/s40170-026-00433-6","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:14:56Z","timestamp":1778577296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Normoxic HIF\u03b1-mediated metabolic rewiring in cancer as a novel therapeutic target of tumor heterogeneity"],"prefix":"10.1186","volume":"14","author":[{"given":"Ana\u00eds","family":"S\u00e1nchez-Castillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo G. E.","family":"Lommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Consten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Savelkouls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie M. O.","family":"Barbeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper M. A.","family":"Rouschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Vooijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim R.","family":"Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"1","key":"433_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"1","key":"433_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL. Hypoxia\u2014a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38\u201347.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"433_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10585-018-9930-x","volume":"35","author":"J Araos","year":"2018","unstructured":"Araos J, Sleeman JP, Garvalov BK. The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies. Clin Exp Metastasis. 2018;35(7):563\u201399.","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"433_CR4","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/cells10071715","volume":"10","author":"MH-R Bao","year":"2021","unstructured":"Bao MH-R, Wong CC-L. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells. 2021;10(7):1715.","journal-title":"Cells"},{"issue":"1","key":"433_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2174\/156652408783565568","volume":"8","author":"MA Vooijs","year":"2008","unstructured":"Vooijs MA, Gort EH, Groot AJ, der Ev W, van Diest PJ. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med. 2008;8(1):60\u20137.","journal-title":"Curr Mol Med"},{"issue":"12","key":"433_CR6","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/2159-8290.CD-14-0250","volume":"4","author":"J Ye","year":"2014","unstructured":"Ye J, Fan J, Venneti S, Wan Y-W, Pawel BR, Zhang J, et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 2014;4(12):1406\u201317.","journal-title":"Cancer Discov"},{"issue":"9","key":"433_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41416-020-0794-x","volume":"122","author":"AL Engel","year":"2020","unstructured":"Engel AL, Lorenz NI, Klann K, M\u00fcnch C, Depner C, Steinbach JP, et al. Serine-dependent redox homeostasis regulates glioblastoma cell survival. Br J Cancer. 2020;122(9):1391\u20138.","journal-title":"Br J Cancer"},{"issue":"15","key":"433_CR8","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1158\/0008-5472.CAN-16-0530","volume":"76","author":"D Samanta","year":"2016","unstructured":"Samanta D, Park Y, Andrabi SA, Shelton LM, Gilkes DM, Semenza GL. PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung MetastasisPHGDH Is Required for Breast Cancer Progression. Cancer Res. 2016;76(15):4430\u201342.","journal-title":"Cancer Res"},{"issue":"2","key":"433_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s42255-020-00329-9","volume":"3","author":"SL Geeraerts","year":"2021","unstructured":"Geeraerts SL, Heylen E, De Keersmaecker K, Kampen KR. The ins and outs of serine and glycine metabolism in cancer. Nat Metabolism. 2021;3(2):131\u201341.","journal-title":"Nat Metabolism"},{"issue":"4","key":"433_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41416-023-02553-y","volume":"130","author":"A S\u00e1nchez-Castillo","year":"2024","unstructured":"S\u00e1nchez-Castillo A, Heylen E, Hounjet J, Savelkouls KG, Lieuwes NG, Biemans R, et al. Targeting serine\/glycine metabolism improves radiotherapy response in non-small cell lung cancer. Br J Cancer. 2024;130(4):568\u201384.","journal-title":"Br J Cancer"},{"issue":"1","key":"433_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41389-024-00540-3","volume":"13","author":"A Sanchez-Castillo","year":"2024","unstructured":"Sanchez-Castillo A, Savelkouls KG, Baldini A, Hounjet J, Sonveaux P, Verstraete P, et al. Sertraline\/chloroquine combination therapy to target hypoxic and immunosuppressive serine\/glycine synthesis-dependent glioblastomas. Oncogenesis. 2024;13(1):39.","journal-title":"Oncogenesis"},{"issue":"1","key":"433_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1535-7163.MCT-20-0480","volume":"20","author":"SL Geeraerts","year":"2021","unstructured":"Geeraerts SL, Kampen KR, Rinaldi G, Gupta P, Planque M, Louros N, et al. Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine\/Glycine Synthesis-Addicted Breast Tumor Growth. Mol Cancer Ther. 2021;20(1):50\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"433_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399\u2013408.","journal-title":"Cell"},{"issue":"11","key":"433_CR14","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.3390\/ijms22115703","volume":"22","author":"V Infantino","year":"2021","unstructured":"Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer cell metabolism in hypoxia: Role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci. 2021;22(11):5703.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"433_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","volume":"30","author":"J Kim","year":"2019","unstructured":"Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metabol. 2019;30(3):434\u201346.","journal-title":"Cell Metabol"},{"key":"433_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","volume":"26","author":"P Vaupel","year":"2007","unstructured":"Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225\u201339.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"433_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0955-0674(00)00194-0","volume":"13","author":"GL Semenza","year":"2001","unstructured":"Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001;13(2):167\u201371.","journal-title":"Curr Opin Cell Biol"},{"key":"433_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10555-007-9066-y","volume":"26","author":"D Liao","year":"2007","unstructured":"Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007;26:281\u201390.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"433_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.18632\/oncotarget.299","volume":"2","author":"W Luo","year":"2011","unstructured":"Luo W, Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget. 2011;2(7):551.","journal-title":"Oncotarget"},{"key":"433_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10555-007-9063-1","volume":"26","author":"DA Chan","year":"2007","unstructured":"Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007;26:333\u20139.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"433_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-\u03b1 prolyl hydroxylase. Cancer Cell. 2005;7(1):77\u201385.","journal-title":"Cancer Cell"},{"issue":"312","key":"433_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","volume":"26","author":"LH Gray","year":"1953","unstructured":"Gray LH, Conger AD, Ebert M, Hornsey S, Scott O. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26(312):638\u201348.","journal-title":"Br J Radiol"},{"key":"433_CR23","unstructured":"Hall EJ, Giaccia AJ. Radiobiology for the Radiologist: Philadelphia; 2006."},{"issue":"1","key":"433_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02000-x","volume":"40","author":"I Telarovic","year":"2021","unstructured":"Telarovic I, Wenger RH, Pruschy M. Interfering with tumor hypoxia for radiotherapy optimization. J Experimental Clin Cancer Res. 2021;40(1):1\u201326.","journal-title":"J Experimental Clin Cancer Res"},{"key":"433_CR25","doi-asserted-by":"crossref","unstructured":"Beckers C, Pruschy M, Vetrugno I, editors. Tumor hypoxia and radiotherapy: a major driver of resistance even for novel radiotherapy modalities. Seminars in Cancer Biology; 2023: Elsevier.","DOI":"10.1016\/j.semcancer.2023.11.006"},{"issue":"5","key":"433_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/sj.bjc.6604939","volume":"100","author":"H Harada","year":"2009","unstructured":"Harada H, Itasaka S, Zhu Y, Zeng L, Xie X, Morinibu A, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer. 2009;100(5):747\u201357.","journal-title":"Br J Cancer"},{"issue":"1","key":"433_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.radmp.2020.01.006","volume":"1","author":"R Huang","year":"2020","unstructured":"Huang R, Zhou P-K. HIF-1 signaling: A key orchestrator of cancer radioresistance. Radiation Med Prot. 2020;1(1):7\u201314.","journal-title":"Radiation Med Prot"},{"issue":"2","key":"433_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ajpath.2011.10.014","volume":"180","author":"M Munksgaard Persson","year":"2012","unstructured":"Munksgaard Persson M, Johansson ME, Monsef N, Planck M, Beckman S, Seckl MJ, et al. HIF-2alpha expression is suppressed in SCLC cells, which survive in moderate and severe hypoxia when HIF-1alpha is repressed. Am J Pathol. 2012;180(2):494\u2013504.","journal-title":"Am J Pathol"},{"issue":"12","key":"433_CR29","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.6061\/clinics\/2012(12)05","volume":"67","author":"E Karetsi","year":"2012","unstructured":"Karetsi E, Ioannou MG, Kerenidi T, Minas M, Molyvdas PA, Gourgoulianis KI, Paraskeva E. Differential expression of hypoxia-inducible factor 1alpha in non-small cell lung cancer and small cell lung cancer. Clin (Sao Paulo). 2012;67(12):1373\u20138.","journal-title":"Clin (Sao Paulo)"},{"issue":"1","key":"433_CR30","doi-asserted-by":"publisher","first-page":"15195","DOI":"10.1038\/s41598-020-72290-2","volume":"10","author":"JJ Renfrow","year":"2020","unstructured":"Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, et al. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020;10(1):15195.","journal-title":"Sci Rep"},{"issue":"1","key":"433_CR31","doi-asserted-by":"publisher","first-page":"10885","DOI":"10.1038\/s41467-024-55243-5","volume":"15","author":"F Wang","year":"2024","unstructured":"Wang F, Dong J, Xu Y, Jin J, Xu Y, Yan X, et al. Turning attention to tumor-host interface and focus on the peritumoral heterogeneity of glioblastoma. Nat Commun. 2024;15(1):10885.","journal-title":"Nat Commun"},{"key":"433_CR32","doi-asserted-by":"publisher","first-page":"1308897","DOI":"10.3389\/fonc.2023.1308897","volume":"13","author":"LM Tesfaw","year":"2023","unstructured":"Tesfaw LM, Dessie ZG, Mekonnen Fenta H. Lung cancer mortality and associated predictors: systematic review using 32 scientific research findings. Front Oncol. 2023;13:1308897.","journal-title":"Front Oncol"},{"issue":"10","key":"433_CR33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"433_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cells8010045","volume":"8","author":"E Moreno Roig","year":"2019","unstructured":"Moreno Roig E, Groot AJ, Yaromina A, Hendrickx TC, Barbeau LM, Giuranno L, et al. HIF-1\u03b1 and HIF-2\u03b1 differently regulate the radiation sensitivity of NSCLC cells. Cells. 2019;8(1):45.","journal-title":"Cells"},{"issue":"9","key":"433_CR35","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.3390\/ijms21093392","volume":"21","author":"P Kong","year":"2020","unstructured":"Kong P, Yu K, Yang M, Almahi WA, Nie L, Chen G, Han W. Micheliolide enhances radiosensitivities of p53-deficient non-small-cell lung cancer via promoting HIF-1\u03b1 degradation. Int J Mol Sci. 2020;21(9):3392.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"433_CR36","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1515\/med-2021-0269","volume":"16","author":"X Ma","year":"2021","unstructured":"Ma X, Wang C, Chen J, Wei D, Yu F, Sun J. circAGFG1 sponges miR-28-5p to promote non-small-cell lung cancer progression through modulating HIF-1\u03b1 level. Open Med. 2021;16(1):703\u201317.","journal-title":"Open Med"},{"issue":"5","key":"433_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","volume":"145","author":"W Luo","year":"2011","unstructured":"Luo W, Hu H, Chang R, Zhong J, Knabel M, O\u2019Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145(5):732\u201344.","journal-title":"Cell"},{"issue":"1","key":"433_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1073\/pnas.1311249111","volume":"111","author":"H-J Wang","year":"2014","unstructured":"Wang H-J, Hsieh Y-J, Cheng W-C, Lin C-P, Lin Y-s, Yang S-F, et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1\u03b1\u2013mediated glucose metabolism. Proc Natl Acad Sci. 2014;111(1):279\u201384.","journal-title":"Proc Natl Acad Sci"},{"key":"433_CR39","doi-asserted-by":"crossref","unstructured":"Heylen E, Verstraete P, Van Aerschot L, Geeraerts SL, Venken T, Timcheva K, et al. Transcription factor NKX2\u20131 drives serine and glycine synthesis addiction in cancer. Br J Cancer. 2023:1\u201317.","DOI":"10.1038\/s41416-023-02216-y"},{"issue":"6","key":"433_CR40","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/cancers13061191","volume":"13","author":"A S\u00e1nchez-Castillo","year":"2021","unstructured":"S\u00e1nchez-Castillo A, Vooijs M, Kampen KR. Linking serine\/glycine metabolism to radiotherapy resistance. Cancers. 2021;13(6):1191.","journal-title":"Cancers"},{"issue":"1","key":"433_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","volume":"32","author":"SK Shukla","year":"2017","unstructured":"Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell. 2017;32(1):71\u201387. e7.","journal-title":"Cancer Cell"},{"issue":"4","key":"433_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","volume":"7","author":"KK Brown","year":"2017","unstructured":"Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov. 2017;7(4):391\u20139.","journal-title":"Cancer Discov"},{"issue":"37","key":"433_CR43","doi-asserted-by":"publisher","first-page":"38458","DOI":"10.1074\/jbc.M406026200","volume":"279","author":"RJ Appelhoff","year":"2004","unstructured":"Appelhoff RJ, Tian Y-M, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004;279(37):38458\u201365.","journal-title":"J Biol Chem"},{"issue":"4","key":"433_CR44","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.cmet.2020.02.017","volume":"31","author":"L Yang","year":"2020","unstructured":"Yang L, Canaveras JCG, Chen Z, Wang L, Liang L, Jang C, et al. Serine catabolism feeds NADH when respiration is impaired. Cell Metabol. 2020;31(4):809\u201321. e6.","journal-title":"Cell Metabol"},{"issue":"7504","key":"433_CR45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature13236","volume":"510","author":"J Fan","year":"2014","unstructured":"Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. Quantitative flux analysis reveals folate-dependent NADPH production. Nature. 2014;510(7504):298\u2013302.","journal-title":"Nature"},{"issue":"3","key":"433_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1042\/BJ20070929","volume":"407","author":"H-Y Kim","year":"2007","unstructured":"Kim H-Y, Gladyshev VN. Methionine sulfoxide reductases: selenoprotein forms and roles in antioxidant protein repair in mammals. Biochem J. 2007;407(3):321\u20139.","journal-title":"Biochem J"},{"issue":"5","key":"433_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1089\/152308603770310239","volume":"5","author":"ER Stadtman","year":"2003","unstructured":"Stadtman ER, Moskovitz J, Levine RL. Oxidation of methionine residues of proteins: biological consequences. Antioxid Redox Signal. 2003;5(5):577\u201382.","journal-title":"Antioxid Redox Signal"},{"issue":"24","key":"433_CR48","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.3390\/cancers13246259","volume":"13","author":"RD Vaes","year":"2021","unstructured":"Vaes RD, Reynders K, Sprooten J, Nevola KT, Rouschop KM, Vooijs M, et al. Identification of potential prognostic and predictive immunological biomarkers in patients with stage I and stage III Non-Small Cell Lung Cancer (NSCLC): a prospective exploratory study. Cancers. 2021;13(24):6259.","journal-title":"Cancers"},{"key":"433_CR49","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1590\/1806-9282.65.10.1295","volume":"65","author":"CU Afsar","year":"2019","unstructured":"Afsar CU, Uysal P. HIF-1\u03b1 Levels in patients receiving chemoradiotherapy for locally advanced non-small cell lung carcinoma. Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira. 2019;65:1295\u20139.","journal-title":"Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"},{"issue":"12","key":"433_CR50","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/gtmb.2020.0173","volume":"24","author":"M Hu","year":"2020","unstructured":"Hu M, Zhang T, Gu M, Li J, Zhang H, Wang Q, et al. Pretreatment to Posttreatment Hypoxia Inducible Factor-1\u03b1 Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations. Genetic Test Mol Biomarkers. 2020;24(12):798\u2013803.","journal-title":"Genetic Test Mol Biomarkers"},{"issue":"1","key":"433_CR51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41392-020-00326-0","volume":"5","author":"H-Q Ju","year":"2020","unstructured":"Ju H-Q, Lin J-F, Tian T, Xie D, Xu R-H. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target therapy. 2020;5(1):231.","journal-title":"Signal Transduct Target therapy"},{"issue":"8","key":"433_CR52","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1074\/jbc.M110978200","volume":"277","author":"A Minchenko","year":"2002","unstructured":"Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase\/fructose-2, 6-bisphosphatase-3 (PFKFB3) gene: its possible role in the Warburg effect. J Biol Chem. 2002;277(8):6183\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"433_CR53","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.yexmp.2009.01.003","volume":"86","author":"A Yalcin","year":"2009","unstructured":"Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase\/fructose-2, 6-bisphosphatases in cancer. Exp Mol Pathol. 2009;86(3):174\u20139.","journal-title":"Exp Mol Pathol"},{"key":"433_CR54","doi-asserted-by":"crossref","unstructured":"Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012;491(7424):458\u201362. 61.","DOI":"10.1038\/nature11540"},{"key":"433_CR55","doi-asserted-by":"crossref","unstructured":"Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA. 2012;109(18):6904\u20139.","DOI":"10.1073\/pnas.1204176109"},{"issue":"3","key":"433_CR56","doi-asserted-by":"publisher","first-page":"zcad032","DOI":"10.1093\/narcan\/zcad032","volume":"5","author":"MR Pandkar","year":"2023","unstructured":"Pandkar MR, Raveendran A, Biswas K, Mutnuru SA, Mishra J, Samaiya A, et al. PKM2 dictates the poised chromatin state of PFKFB3 promoter to enhance breast cancer progression. NAR cancer. 2023;5(3):zcad032.","journal-title":"NAR cancer"},{"issue":"22","key":"433_CR57","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-17-1589","volume":"77","author":"H Yoshino","year":"2017","unstructured":"Yoshino H, Nohata N, Miyamoto K, Yonemori M, Sakaguchi T, Sugita S, et al. PHGDH as a key enzyme for serine biosynthesis in HIF2\u03b1-targeting therapy for renal cell carcinoma. Cancer Res. 2017;77(22):6321\u20139.","journal-title":"Cancer Res"},{"issue":"8","key":"433_CR58","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1172\/JCI38443","volume":"119","author":"WY Kim","year":"2009","unstructured":"Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, et al. HIF2\u03b1 cooperates with RAS to promote lung tumorigenesis in mice. J Clin Investig. 2009;119(8):2160\u201370.","journal-title":"J Clin Investig"},{"key":"433_CR59","doi-asserted-by":"crossref","unstructured":"Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, et al. HIF-2\u03b1 deletion promotes Kras-driven lung tumor development. Proc Nat Acad Sci. 2010;107(32):14182-7.","DOI":"10.1073\/pnas.1001296107"},{"issue":"7650","key":"433_CR60","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature22056","volume":"544","author":"OD Maddocks","year":"2017","unstructured":"Maddocks OD, Athineos D, Cheung EC, Lee P, Zhang T, Van Den Broek NJ, et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 2017;544(7650):372\u20136.","journal-title":"Nature"},{"key":"433_CR61","doi-asserted-by":"crossref","unstructured":"Franovic A, Holterman CE, Payette J, Lee S. Human cancers converge at the HIF-2\u03b1 oncogenic axis. Proc Nat Acad Sci. 2009;106(50):21306-11.","DOI":"10.1073\/pnas.0906432106"},{"issue":"4","key":"433_CR62","first-page":"353","volume":"49","author":"YK Yoon","year":"2010","unstructured":"Yoon YK, Kim HP, Han SW, Oh DY, Im SA, Bang YJ, Kim TY. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Molecular Carcinogenesis: Published in cooperation with the University of Texas. MD Anderson Cancer Cent. 2010;49(4):353\u201362.","journal-title":"MD Anderson Cancer Cent"},{"issue":"9","key":"433_CR63","doi-asserted-by":"publisher","first-page":"e814","DOI":"10.1038\/cddis.2013.312","volume":"4","author":"J Chen","year":"2013","unstructured":"Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, et al. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Cell Death Dis. 2013;4(9):e814\u2013e.","journal-title":"Cell Death Dis"},{"issue":"1","key":"433_CR64","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/ncomms1786","volume":"3","author":"H Harada","year":"2012","unstructured":"Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun. 2012;3(1):783.","journal-title":"Nat Commun"},{"key":"433_CR65","doi-asserted-by":"crossref","unstructured":"Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5(5):429\u201341.","DOI":"10.1016\/S1535-6108(04)00115-1"},{"key":"433_CR66","doi-asserted-by":"crossref","unstructured":"Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K, et al. The Akt\/mTOR pathway assures the synthesis of HIF-1\u03b1 protein in a glucose-and reoxygenation-dependent manner in irradiated tumors. J Biol Chem. 2009;284(8):5332\u201342.","DOI":"10.1074\/jbc.M806653200"},{"key":"433_CR67","doi-asserted-by":"crossref","unstructured":"Patel SA, Simon MC. Biology of hypoxia-inducible factor-2\u03b1 in development and disease. Cell Death Differ. 2008;15(4):628\u201334.","DOI":"10.1038\/cdd.2008.17"},{"key":"433_CR68","doi-asserted-by":"crossref","unstructured":"Zhao J, Du F, Luo Y, Shen G, Zheng F, Xu B. The emerging role of hypoxia-inducible factor-2 involved in chemo\/radioresistance in solid tumors. Cancer Treat Rev. 2015;41(7):623\u201333.","DOI":"10.1016\/j.ctrv.2015.05.004"},{"key":"433_CR69","doi-asserted-by":"crossref","unstructured":"Albadari N, Deng S, Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov. 2019;14(7):667\u201382.","DOI":"10.1080\/17460441.2019.1613370"},{"key":"433_CR70","doi-asserted-by":"crossref","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinicaltranslation. J Clin Invest. 2022;132(11).","DOI":"10.1172\/JCI159839"},{"key":"433_CR71","doi-asserted-by":"crossref","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249\u201357.","DOI":"10.1038\/35025220"},{"key":"433_CR72","doi-asserted-by":"crossref","unstructured":"Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res. 2009;172(6):653\u201365.","DOI":"10.1667\/RR1926.1"},{"key":"433_CR73","doi-asserted-by":"crossref","unstructured":"Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8(6):425\u201337.","DOI":"10.1038\/nrc2397"},{"key":"433_CR74","doi-asserted-by":"crossref","unstructured":"Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699\u2013728.","DOI":"10.1007\/s00018-018-2956-z"},{"issue":"3","key":"433_CR75","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.radonc.2011.05.049","volume":"99","author":"VE Zannella","year":"2011","unstructured":"Zannella VE, Cojocari D, Hilgendorf S, Vellanki RN, Chung S, Wouters BG, Koritzinsky M. AMPK regulates metabolism and survival in response to ionizing radiation. Radiother Oncol. 2011;99(3):293\u20139.","journal-title":"Radiother Oncol"},{"issue":"2","key":"433_CR76","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3892\/mmr.2017.6852","volume":"16","author":"Q He","year":"2017","unstructured":"He Q, Li J, Dong F, Cai C, Zou X. LKB1 promotes radioresistance in esophageal cancer cells exposed to radiation, by suppression of apoptosis and activation of autophagy via the AMPK pathway. Mol Med Rep. 2017;16(2):2205\u201310.","journal-title":"Mol Med Rep"},{"issue":"5","key":"433_CR77","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.3892\/ol.2016.4339","volume":"11","author":"H Jin","year":"2016","unstructured":"Jin H, Gao S, Guo H, Ren S, Ji F, Liu Z, Chen X. Re-sensitization of radiation resistant colorectal cancer cells to radiation through inhibition of AMPK pathway. Oncol Lett. 2016;11(5):3197\u2013201.","journal-title":"Oncol Lett"},{"issue":"20","key":"433_CR78","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-12-0858","volume":"18","author":"TW Meijer","year":"2012","unstructured":"Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18(20):5585\u201394.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"433_CR79","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ijms20020238","volume":"20","author":"A Nagao","year":"2019","unstructured":"Nagao A, Kobayashi M, Koyasu S, Chow CC, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci. 2019;20(2):238.","journal-title":"Int J Mol Sci"},{"key":"433_CR80","doi-asserted-by":"crossref","unstructured":"Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, et al. Multiple factors affecting cellular redoxstatus and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol. 2007;27(3):912\u201325.","DOI":"10.1128\/MCB.01223-06"},{"key":"433_CR81","doi-asserted-by":"crossref","unstructured":"Tennant D, Frezza C, MacKenzie E, Nguyen Q, Zheng L, Selak M, et al. Reactivating HIF prolyl hydroxylases under hypoxiaresults in metabolic catastrophe and cell death. Oncogene. 2009;28(45):4009\u201321.","DOI":"10.1038\/onc.2009.250"},{"key":"433_CR82","doi-asserted-by":"crossref","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitorof \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17\u201330.","DOI":"10.1016\/j.ccr.2010.12.014"},{"key":"433_CR83","doi-asserted-by":"crossref","unstructured":"Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, et al. Reactive oxygen speciesgenerated at mitochondrial complex III stabilize hypoxia-inducible factor-1\u03b1 during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000;275(33):25130\u20138.","DOI":"10.1074\/jbc.M001914200"},{"key":"433_CR84","doi-asserted-by":"crossref","unstructured":"Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, et al. Oxygen sensing requiresmitochondrial ROS but not oxidative phosphorylation. Cell Metab. 2005;1(6):409\u201314.","DOI":"10.1016\/j.cmet.2005.05.002"},{"key":"433_CR85","doi-asserted-by":"crossref","unstructured":"Semenza GL. HIF-1 mediates metabolic responses tointratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664\u201371.","DOI":"10.1172\/JCI67230"},{"key":"433_CR86","doi-asserted-by":"crossref","unstructured":"Zelzer E, Levy Y, Kahana C, Shilo B-Z,Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1\u03b1\/ARNT. EMBO J. 1998;17(17):5085\u201394.","DOI":"10.1093\/emboj\/17.17.5085"},{"key":"433_CR87","doi-asserted-by":"crossref","unstructured":"Br\u00fcne B, Zhou J. Nitric oxide and superoxide: interference with hypoxic signaling. Cardiovasc Res. 2007;75(2):275\u201382","DOI":"10.1016\/j.cardiores.2007.03.005"},{"key":"433_CR88","doi-asserted-by":"crossref","unstructured":"Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, et al. Loss of PTEN facilitates HIF-1-mediated geneexpression. Genes Dev. 2000;14(4):391\u20136.","DOI":"10.1101\/gad.14.4.391"},{"key":"433_CR89","doi-asserted-by":"crossref","unstructured":"Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation oftumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1\u03b1. Genes Dev. 2000;14(1):34\u201344.","DOI":"10.1101\/gad.14.1.34"},{"key":"433_CR90","unstructured":"Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu M-M, et al. Modulation of hypoxia-inducible factor 1\u03b1 expression by the epidermal growthfactor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis andtherapeutics. Cancer Res. 2000;60(6):1541\u20135."},{"key":"433_CR91","doi-asserted-by":"crossref","unstructured":"Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, et al. The tumoursuppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271\u20135.","DOI":"10.1038\/20459"},{"key":"433_CR92","doi-asserted-by":"crossref","unstructured":"Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1)synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21(12):3995\u20134004.","DOI":"10.1128\/MCB.21.12.3995-4004.2001"},{"key":"433_CR93","doi-asserted-by":"crossref","unstructured":"Pollard P, Briere J, Alam N, Barwell J, Barclay E, Wortham N, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1\u03b1 in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005;14(15):2231\u20139.","DOI":"10.1093\/hmg\/ddi227"},{"issue":"2","key":"433_CR94","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0360-3016(02)04579-0","volume":"56","author":"P Burri","year":"2003","unstructured":"Burri P, Djonov V, Aebersold DM, Lindel K, Studer U, Altermatt HJ, et al. Significant correlation of hypoxia-inducible factor-1\u03b1 with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiation Oncology* Biology* Phys. 2003;56(2):494\u2013501.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"5","key":"433_CR95","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0360-3016(02)02848-1","volume":"53","author":"MI Koukourakis","year":"2002","unstructured":"Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiation Oncology* Biology* Phys. 2002;53(5):1192\u2013202.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"4","key":"433_CR96","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","volume":"9","author":"R Vergis","year":"2008","unstructured":"Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008;9(4):342\u201351.","journal-title":"Lancet Oncol"},{"issue":"7","key":"433_CR97","first-page":"2911","volume":"61","author":"DM Aebersold","year":"2001","unstructured":"Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL. Expression of hypoxia-inducible factor-1\u03b1: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61(7):2911\u20136.","journal-title":"Cancer Res"},{"issue":"2","key":"433_CR98","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ccr.2005.06.016","volume":"8","author":"BJ Moeller","year":"2005","unstructured":"Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, Dewhirst MW. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8(2):99\u2013110.","journal-title":"Cancer Cell"},{"issue":"22","key":"433_CR99","doi-asserted-by":"publisher","first-page":"8139","DOI":"10.1158\/0008-5472.CAN-03-2301","volume":"64","author":"X Zhang","year":"2004","unstructured":"Zhang X, Kon T, Wang H, Li F, Huang Q, Rabbani ZN, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1\u03b1. Cancer Res. 2004;64(22):8139\u201342.","journal-title":"Cancer Res"},{"key":"433_CR100","doi-asserted-by":"crossref","unstructured":"Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, et al. HIF2\u03b1 inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Nat Acad Sci. 2009;106(34):14391\u20136.","DOI":"10.1073\/pnas.0907357106"}],"container-title":["Cancer & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-026-00433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-026-00433-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-026-00433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:33:12Z","timestamp":1778596392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40170-026-00433-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1186\/s40170-026-00433-6","relation":{},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}